The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy
- 16 June 2006
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 8 (8) , 1056-1067
- https://doi.org/10.1002/jgm.931
Abstract
Background: The most extensively investigated strategy of suicide gene therapy for treatment of cancer is the transfer of the herpes simplex virus thymidine kinase (HSV‐TK) gene followed by administration of antiviral prodrugs such as acyclovir (ACV) and ganciclovir (GCV). The choice of the agent that can stimulate HSV‐TK enzymatic activity is one of the determinants of the usefulness of this strategy. Previously, we found that a diterpenoid, scopadulciol (SDC), produced a significant increase in the active metabolite of ACV. This suggests that SDC may play a role in the HSV‐TK/prodrug administration system.Methods: The anticancer effect of SDC was evaluated in HSV‐TK‐expressing (TK+) cancer cells and nude mice bearing TK+ tumors. In vitro and in vivo enzyme assays were performed using TK+ cells and tumors. The phosphorylation of ACV monophosphate (ACV‐MP) was measured in TK− cell lysates. The pharmacokinetics of prodrugs was evaluated by calculating area‐under‐the‐concentration‐time‐curve values.Results: SDC stimulated HSV‐TK activity in TK+ cells and tumors, and increased GCV‐TP levels, while no effect of SDC was observed on the phosphorylation of ACV‐MP to ACV‐TP by cellular kinases. The SDC/prodrug combination altered the pharmacokinetics of the prodrugs. In accord with these findings, SDC enhanced significantly the cell‐killing activity of prodrugs. The bystander effect was also significantly augmented by the combined treatment of ACV/GCV and SDC.Conclusions: SDC was shown to be effective in the HSV‐TK/prodrug administration system and improved the efficiency of the bystander effect of ACV and GCV. The findings will be considerably valuable with respect to the use of GCV in lower doses and less toxic ACV. This novel strategy of drug combination could provide benefit to HSV‐TK/prodrug gene therapy. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 49 references indexed in Scilit:
- Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapyGene Therapy, 2002
- Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-mediated gene therapy is influenced by the expression of connexin43 in the target cellsCancer Gene Therapy, 2001
- Two-drug combinations that increase apoptosis and modulate Bak and Bcl-XL expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinaseCancer Gene Therapy, 2000
- Potentiation of ganciclovir toxicity in the herpes simplex virus thymidine kinase/ganciclovir administration system by ponicidinCancer Gene Therapy, 2000
- Use of protamine to augment adenovirus-mediated cancer gene therapyGene Therapy, 1999
- Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapyGene Therapy, 1997
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- A comparison of the antiviral agents 2′-nor-2′-deoxyguanosine and acyclovir: Uptake and phosphorylation in tissue culture and kinetics of in vitro inhibition of viral and cellular DNA polymerases by their respective triphosphatesBiochemical and Biophysical Research Communications, 1983
- Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG)Biochemical and Biophysical Research Communications, 1982
- Induction of Both Thymidine and Deoxycytidine Kinase Activity by Herpes VirusesJournal of General Virology, 1974